Core Viewpoint - The electric grid equipment sector is experiencing a significant structural change, with domestic investments increasing while foreign capital is retreating, indicating a new growth phase for the industry in 2026 [2][4]. Group 1: Market Performance and Key Developments - On January 7, 2026, China XD Electric (601179.SH) saw a strong surge, nearing its historical high of 11.08 yuan, following its successful bid for a 1.447 billion yuan project from the State Grid [2][3]. - The electric grid equipment index rose by 1.88% on the same day, reaching a one-month high, with significant gains observed in other companies like Sanbian Technology (002112.SZ) and Far East Holdings (600869.SH) [3]. - In 2025, the electric grid equipment index increased by 33%, reaching a historical peak, driven by accelerated investments from the State Grid and high demand for overseas grid upgrades [3][5]. Group 2: Investment Trends and Structural Changes - The total market size for domestic electric grid equipment is projected to exceed 2 trillion yuan in 2025, with a year-on-year growth of 15%, supported by stable investments from the State Grid and Southern Grid [5]. - The bidding amount for State Grid's transmission and transformation equipment reached 91.9 billion yuan in 2025, reflecting a 26% year-on-year increase, with significant growth in the bidding for ultra-high voltage transformers and combined electrical devices [5]. - The structural changes in investment direction are leading to a divergence in the performance of different segments within the electric grid equipment industry, with high demand for main grid and transformer exports while some segments face pressure [5][6]. Group 3: Future Outlook and Opportunities - The acceleration of ultra-high voltage project approvals is expected to provide clear guidance for State Grid's investment growth in 2026, with projections for four new direct current lines to be approved [6]. - The demand for electric transformers is anticipated to remain high due to aging infrastructure in the U.S. and a significant supply gap, presenting a historic opportunity for domestic companies to expand internationally [7]. - The introduction of next-generation solid-state transformers, which can improve power supply efficiency to over 90%, is expected to be a key development in 2026, with domestic companies likely to benefit from high-margin orders [7].

| < 日 | | | SHFE更全 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | AU.SHF | | | | | | 995.74 ªª | | | 1005.28 | 总手 | 1.11万 | 万得 盘口 | | | -9.54 | | -0.95% 开盘 | 999.40 现手 | | 5 | | | | 最高价 | | 1000.56 持 色 | 12.61万 | 外盘 | | 4927 | | | 最低价 | | 995.20 指 仓 | | -9 内 盘 | | 6209 | | | 分时 | 周K | EF 日K | | 月K | 更多 | (0) | | | 暨加 | | | | 均价:998.45 | | | | | 1015.36 | | | | 1.00% | 英元 DICLES | 995.90 995.88 | T 1 | | | | | | | | 995.86 995.84 | 1 1 | | | | | | 0.00% | | 995.80 | 5 | | 1005.28 | | | | ...

Core Viewpoint - The establishment of a comprehensive punishment and prevention system for financial fraud is fundamental to purifying the ecological environment of the capital market [1] Group 1: Regulatory Actions - The China Securities Regulatory Commission (CSRC) has made significant progress in combating financial fraud, with 159 cases investigated and 111 administrative penalties imposed since the beginning of 2024, amounting to fines of 8.1 billion [2] - The introduction of the special representative litigation system has enhanced the interconnectivity of administrative, criminal, and civil actions, contributing positively to a healthy investment environment [2] Group 2: Challenges in Enforcement - Sole reliance on judicial and regulatory enforcement is insufficient, as the complexity of financial fraud makes it difficult for regulators to detect all violations [3] - Financial fraud is characterized by private information and information asymmetry, necessitating a dual approach that combines public enforcement with market self-regulation [3] Group 3: Improvement of Legal Framework - The current special representative litigation system has limitations, with very few cases actually initiated despite numerous financial fraud incidents, indicating a need to lower the entry barriers for such lawsuits [4] - The complexity of defining eligible representatives and the ambiguity in compensation distribution hinder the effectiveness of the self-regulatory system [4] Group 4: Enhancing Market Self-Regulation - Reducing the barriers for the special representative litigation system will lower the costs of market self-regulation and increase the costs for financial fraud [5] - Establishing a civil compensation priority before administrative penalties could incentivize the special representative litigation system, addressing issues related to enforcement and compensation collection [5]

2026.01.07 今年的CES（国际消费电子展）演讲中，算力焦虑是一个不断被提起的话题。 当地时间1月5日，在与OpenAI总裁格雷格·布洛克曼（Greg Brockman）的对话中，AMD CEO苏姿丰笑 言，每次见到格雷格·布洛克曼，他都在说需要更多算力。 按照苏姿丰的预测，未来几年内需要将全世界的计算能力增加100倍。英伟达CEO黄仁勋给出的数据则 是，模型规模以每年10倍的速度增长，推理模型的输出每年增长5倍。为匹配算力需求，英伟达透露， 最新架构芯片吞吐量是前一代的10倍，苏姿丰则放话，有望4年内将AI芯片性能提升1000倍。 但如果考虑到芯片晶体管每年密度提升的速度，每年实现10倍的性能提升并不容易。在1月6日与第一财 经等媒体一个半小时的对话中，黄仁勋换上了一件新皮衣，谈话中多次提到芯片工艺技术逼近物理极 限，为了应对这个挑战，英伟达需要在半导体工艺之外做到更多。 本文字数：4318，阅读时长大约7分钟 作者 |第一财经 郑栩彤 刘佳 封图 |第一财经记者刘佳摄 英伟达走向了从芯片到整个计算机系统、数据中心的协同优化路径，在算力芯片之外看到更多。在对话 中，黄仁勋讲到英伟达在存储、能源、模型 ...

Core Insights - Gaode is transitioning from a mapping service to a local life service super entrance, as evidenced by the launch of the "Street Ranking" which has gained significant traction in a short period [1][5] User Growth and Engagement - The "Street Ranking" accumulated over 660 million users within 100 days of its launch, with more than 860,000 merchants actively joining the platform [1][5] - On the first day of its launch, the user base exceeded 40 million, and by October 2025, the daily active users surpassed 70 million, showcasing a "phenomenal" growth in a saturated market [3][5] Merchant Performance - The average revenue of the 860,000 merchants increased by over 270% month-on-month, indicating the platform's effectiveness in enhancing merchant operations [5] User Experience and Trust - The "Street Ranking" utilizes real user behavior data, such as navigation and in-store visits, to create rankings, thereby addressing issues of trust and authenticity in local service reviews [4][10] - Users reported a significant reduction in decision-making costs when selecting local services, as the platform provides reliable recommendations based on actual consumer behavior [7][10] Technological Advancements - The 2026 upgrade of the "Street Ranking" introduced 6,553 dynamic seasonal rankings and 1,550 category rankings, expanding its coverage to global listings across over 200 countries [8][10] - New features like "Flying Street View" and AR capabilities enhance user interaction and provide immersive experiences, showcasing Gaode's technological edge in the local service market [10][11] Market Positioning - Gaode's strategy positions it as a key player in the local life service sector, leveraging its extensive data assets and AI capabilities to create a differentiated credit system for local services [4][8][11] - The platform aims to reshape the local consumption credit system and growth logic, emphasizing the importance of genuine consumer experiences in driving business success [11]

2026.01.07 本文字数：2031，阅读时长大约4分钟 作者 |第一财经 林志吟 从本月起，首版《商业健康保险创新药品目录》（下称"商保创新药目录"）开始在各地启用。 作为普惠型商业健康保险产品代表之一，惠民保近年来得到普及。而惠民保参保者，尤其是一些重疾患 者，到底能从商保创新药目录获益多少？ 首版商保创新药目录在医保目录之外，收录了19种临床价值突出但超出医保支付能力的创新药。从治疗 领域看，这些药品覆盖肿瘤、罕见病、神经退行性疾病及代谢类疾病多个关键领域，具体包括CAR-T治 疗药物、阿尔茨海默症治疗药品、神经母细胞瘤和戈谢病等罕见病治疗药品，填补了基本医保目录空 白。 从目前看，商保创新药目录的落地，能让惠民保参保者获益多少，要取决于惠民保产品承接、相关创新 药进院情况等。 进入商保创新药目录的创新药，最后的推广使用要落实在医院端，当前看，这些高价高值创新药在打通 入院"最后一公里"上，仍有障碍。 有CAR-T药企对第一财经记者表示，他们进入商保创新药目录的CAR-T药物，目前还未看到可以直接入 院的。 有创新药进入商保创新药目录的罕见病药企对第一财经记者表示，产品能否入院，要看每家医院的要求 ...

Core Viewpoint - The stock of Guosheng Technology (603778.SH) has been suspended due to excessive price increases that deviate from its fundamentals, with a cumulative increase of 370.20% from October 31, 2025, to January 6, 2026, indicating potential market overheating and irrational speculation risks [2][3]. Company Overview - Guosheng Technology, formerly known as Qianjing Garden, transitioned from landscape engineering to a dual business model of "landscape + photovoltaic" after acquiring stakes in seven subsidiaries for 154 million yuan in November 2022 [4]. - The company has faced significant losses, with cumulative losses exceeding 400 million yuan from 2020 to 2022, and net losses of 68.88 million yuan in 2023, 106 million yuan in 2024, and 151 million yuan in the first three quarters of 2025 [4]. Financial Metrics - The company's price-to-book ratio stands at 17.47, significantly higher than the industry average of 3.22, indicating a bubble in its stock price [3]. - As of September 30, 2025, Guosheng Technology's debt-to-asset ratio was 70.52%, reflecting a 4.04 percentage point increase from the previous quarter and a 6.32 percentage point increase year-on-year [5]. Investment Activities - The company announced a 230 million yuan investment in Guosheng Global New Energy for a solid-state battery manufacturing project, primarily funded by bank loans, which raises concerns about its short-term debt repayment capacity [5]. - On November 25, 2025, Guosheng Technology disclosed plans to acquire 100% of Fuyue Technology for 240.6 million yuan, prompting inquiries from the Shanghai Stock Exchange regarding the valuation and funding sources for this acquisition [6].

从本月起，首版《商业健康保险创新药品目录》（下称"商保创新药目录"）开始在各地启用。 作为普惠型商业健康保险产品代表之一，惠民保近年来得到普及。而惠民保参保者，尤其是一些重疾患 者，到底能从商保创新药目录获益多少？ 首版商保创新药目录在医保目录之外，收录了19种临床价值突出但超出医保支付能力的创新药。从治疗 领域看，这些药品覆盖肿瘤、罕见病、神经退行性疾病及代谢类疾病多个关键领域，具体包括CAR-T治 疗药物、阿尔茨海默症治疗药品、神经母细胞瘤和戈谢病等罕见病治疗药品，填补了基本医保目录空 白。 以CAR-T药物为例，有血液肿瘤医生对第一财经记者表示，对于一些真正难治的血液瘤患者而言， CAR-T是较好的治疗手段，在没有这类疗法之前，一些患者的中位生存期只有半年，但有了这种治疗手 段后，有部分患者的生存期可以提高到五年及五年以上，但CAR-T疗法费用高昂，无法在患者中得到普 及。商保支付的话，可以减轻患者费用负担。 值得注意的是，该产品也标注称"必须为住院期间使用，且合并在住院医疗费用中一并结算并上传到国 家医保平台的全自费药品费用才可纳入"。 换言之，如果进入商保创新药目录的创新药无法顺利入院的话，参保的患 ...

芯片股走强，纳芯微涨超13%，华虹半导体涨5%。 | 小朋与六七十一-VV | 78.050 | -2.19% | | --- | --- | --- | | 9868.HK | | | | 零跑汽车 | 49.440 | -2.10% | | 9863.HK | | | | 理想汽车-W | 66.800 | -1.69% | | 2015.HK | | | | 毕 里 毕 里 - W | 211.000 | -1.59% | | 9626.HK | | | | 小米集团-W | 38.160 | -1.55% | | 1810.HK | | | | 美团-W | 104.500 | -1.51% | | 3690.HK | | | 医药股尾盘拉升，荣昌生物涨近13%，凯莱英、泰格医药等涨超8%。 | 名称 | 现价 | 涨跌幅 ◆ | | --- | --- | --- | | 荣昌生物 | 91.700 | 12.93% | | 9995.HK | | | | 中国抗体-B | 1.590 | 11.97% | | 3681.HK | | | | 创胜集团-B | 2.410 | 11.57% | | ...

Core Insights - The People's Bank of China reported that as of the end of December, the country's gold reserves reached 74.15 million ounces, marking an increase of 30,000 ounces and representing the 14th consecutive month of gold accumulation [1]. Group 1: Gold Reserves - China's gold reserves stood at 74.15 million ounces at the end of December, reflecting a month-on-month increase of 30,000 ounces [1]. - This increase in gold reserves indicates a sustained strategy of accumulation by the People's Bank of China over the past 14 months [1]. Group 2: Foreign Currency Reserves - As of December, China's foreign currency reserves amounted to approximately 33,578.69 billion USD, showing a slight increase from 33,463.72 billion USD in November [2]. - The IMF reserve position rose from 110.59 billion USD in November to 111.79 billion USD in December [2]. - Special Drawing Rights (SDRs) increased marginally from 557.16 billion USD to 558.24 billion USD during the same period [2]. Group 3: Other Reserve Assets - Other reserve assets showed a minor improvement, with a change from -1.43 billion USD in November to -0.15 billion USD in December [2]. - The total reserves, including all categories, increased from 37,236.51 billion USD in November to 37,443.07 billion USD in December [2].